4-(3-cyanophenyl)butanoic acid | 92422-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-cyanophenyl)butanoic acid
• 英文别名: 4-(3-cyanophenyl)butyric acid
• CAS: 92422-91-8
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: JGIIENUTAXNMKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  363.9±17.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-cyanophenyl)butanoic acid 在 Lindlar's catalyst 2,4,6-三异丙基苯磺酰叠氮化物 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 、 lithium hexamethyldisilazane 作用下， 以 乙醚 、 乙醇 为溶剂， -78.0~25.0 ℃ 、310.27 kPa 条件下， 反应 1.28h， 生成 Methyl 4-(3-cyanophenyl)-2-[(4-phenylbenzoyl)amino]butanoate
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  间溴苯甲腈 在 Lindlar's catalyst 哌啶 、 chromium(VI) oxide 、 四(三苯基膦)钯 、 硫酸 、 氢气 作用下， 以 乙醇 、 丙酮 为溶剂， 25.0~80.0 ℃ 、310.27 kPa 条件下， 反应 5.25h， 生成 4-(3-cyanophenyl)butanoic acid
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y

文献信息

• Ligand‐Controlled Regiodivergence in Nickel‐Catalyzed Hydroarylation and Hydroalkenylation of Alkenyl Carboxylic Acids**
  作者：Zi‐Qi Li、Yue Fu、Ruohan Deng、Van T. Tran、Yang Gao、Peng Liu、Keary M. Engle

  DOI：10.1002/anie.202010840

  日期：2020.12.14

  the ligand environment around the metal center dictates the regiochemical outcome. Markovnikov hydrofunctionalization products are obtained under mild ligand‐free conditions, with up to 99 % yield and >20:1 selectivity. Alternatively, anti‐Markovnikov products can be accessed with a novel 4,4‐disubstituted Pyrox ligand in excellent yield and >20:1 selectivity. Both electronic and steric effects on the

  据报道，镍催化的未活化链烯基羧酸的区域发散性氢芳基化和氢烯基化，从而金属中心周围的配体环境决定了区域化学结果。Markovnikov加氢官能化产物是在无配体的温和条件下获得的，产率高达99％，选择性> 20：1。另外，可以使用新型的4,4-二取代的Pyrox配体获得抗Markovnikov产物，并具有优异的收率和> 20：1的选择性。对配体的电子和空间效应都有助于高产率和选择性。机理研究表明，最佳配体引起的营业额限制和选择性决定步骤发生了变化。DFT计算表明，在反马尔科夫尼科夫途径中，
• Cyclic imino derivatives and pharmaceutical compositions containing them
  申请人：Karl Thomae GmbH

  公开号：US05541343A1

  公开（公告）日：1996-07-30

  The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。
• Novel Indoline Compounds
  申请人：LEBRETON Luc

  公开号：US20080119465A1

  公开（公告）日：2008-05-22

  Sulfonylindoline compounds of formula I, wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.

  公式I的磺胺基吲哚化合物，其中R1至R4，Y和Z具有定义的含义，一种制备这种化合物的过程，以及用作药用活性物质，特别用于治疗或抑制神经退行性疾病、心血管疾病、炎症性疾病、高胆固醇血症、血脂异常、肥胖或糖尿病。
• [EN] TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES<br/>[FR] MACROCYCLES PEPTIDOMIMÉTIQUES RÉTICULÉS PAR TRIAZOLE ET PAR THIOÉTHER
  申请人：AILERON THERAPEUTICS INC

  公开号：WO2013123267A1

  公开（公告）日：2013-08-22

  Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.

  本文提供了肽类模拟大环和使用这种大环治疗疾病的方法。
• [EN] PEPTIDOMIMETIC MACROCYCLES<br/>[FR] MACROCYCLES PEPTIDOMIMÉTIQUES
  申请人：AILERON THERAPEUTICS INC

  公开号：WO2013123266A1

  公开（公告）日：2013-08-22

  Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.

  本文提供了肽类模拟大环化合物及其在治疗疾病方面的使用方法。